Pneumologie : ce qui a changé en 2025
Abstract
Pulmonary sarcoidosis is typically treated with prednisone, but its side effects are prompting the search for alternatives. The PREDMETH study compared methotrexate and prednisone, demonstrating similar efficacy on lung function at 24 weeks. Methotrexate causes fewer metabolic effects but more gastrointestinal and liver disturbances. These results support an alternative approach in sarcoidosis. Non-cystic fibrosis bronchiectasis (NCFBE) has long been limited to repeating what works in cystic fibrosis patients, such as supportive treatments, inhaled antibiotics and macrolides. The first phase 3 trial for a treatment targeting specifically neutrophil inflammation: brensocatib, is presented in this article.
Fields of Study & Subjects
Sarcoidosis and Beryllium Toxicity Research
Cystic Fibrosis Research Advances
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Publication details
- Journal / source
- JMIG
- Volume
- 22
- Issue
- 945
- Pages
- 71–74
- Publication date
- 1 January 2026
- Language
- EN